Videos

2017 Updates on Myeloproliferative Neoplasms

Dr. Ruben Mesa (@mpdrc) gives updates from the 2016 American Society of Hematology relevant to the treatment of essential thrombocythemia, polycythemia vera, myelofibrosis and systemic mastocytosis.

Back to Top


Updates on Myeloproliferative Neoplasms (MPNs): Summer 2016

Dr. Mesa discusses key MPN updates from the American Society of Clinical Oncology (ASCO) meeting in Chicago and the European Hematology Association(EHA) meeting.
Summer 2016

Back to Top


Dr. Ruben Mesa, Mayo Clinic Cancer Center provides an update on the latest advances in MPN for the Summer 2015

In the following video, Ruben Mesa. M.D., deputy director, Mayo Clinic Cancer Center, provides an update on the latest advances in MPN (Myeloproliferative Neoplasm) treatments from the Summer Medical Meeting (American Society of Clinical Oncology (ASCO) and European Hematology Association Meeting (EHA)).

Back to Top


Myelofibrosis Update 2015 - Mayo Clinic

In this second video in the series, Myeloproliferative Neoplasms 2015, Ruben Mesa, M.D., professor and hematologist at Mayo Clinic in Arizona, discusses the treatment and management of myelofibrosis as well as shares highlights from the 56th Annual American Society of Hematology (ASH) meeting in San Francisco, December 2014.

Back to Top


Essential Thrombocythemia Update 2015 - Mayo Clinic

In this final video in the series, Myeloproliferative Neoplasms 2015, Ruben Mesa, M.D., professor and hematologist at Mayo Clinic in Arizona, discusses updates on the treatment and management of essential thrombocythemia as well as shares highlights from the 56th Annual American Society of Hematology (ASH) meeting in San Francisco, December 2014.

Back to Top


Polycythemia Vera Update 2015 - Mayo Clinic

In this third video in the series, Myeloproliferative Neoplasms 2015, Ruben Mesa, M.D., professor and hematologist at Mayo Clinic in Arizona, discusses updates on the treatment and management of polycythemia vera as well as shares highlights from the 56th Annual American Society of Hematology (ASH) meeting in San Francisco, December 2014.

Back to Top


Why Do MPNs Require a Bone Marrow Biopsy?

Bone marrow biopsies have been described by some as “medieval torture." Certainly, they can be painful, so why do MPN patients need to have bone marrow biopsies? What are doctors and researchers looking for? Drs. Srdan Verstovsek and Jason Gotlib discuss the necessities of bone marrow biopsies for MPN patients: why we need them, what they accomplish, and how they fit into the total diagnostic process.

Back to Top


Bridging the Overlap Gap: Understanding the Natural History of Myelodysplastic/ Myeloproliferative Neoplasm (MDS/MPN)

Different types of MDS/MPN have similar symptoms but profoundly different outcomes. The type and intensity of treatment must be tailored to each patient's type of MDS/MPN. Therefore, it is important to diagnose these diseases accurately.

Back to Top


There is Always Room for Improvement: Changing Role of Chromosome Analysis in MDS and MDS/MPN.

Conventional cytogenetics is a method to analyze chromosomes. Researchers and clinicians use conventional cytogenetics to diagnose blood disorders, predict outcomes in patients with these disorders, and develop new treatments that target genetic changes associated with a disease.

Back to Top


Drivers or Passengers? Genetics of MDS and MDS/MPN

Diagnosis of MDS or MDS/MPN must begin with morphology (analysis of the form and structure of patient blood or bone marrow cells). When used alone, today's advanced techniques to study genes and chromosomes don't give enough information to find out what type of MDS or MDS/MPN a patient has.

Back to Top


Suffering from an Identity Crisis: Medications and Measures of Treatment Response in MDS/MPN.

Advances in treatment for MDS/MPN are not keeping pace with the rapid improvement in understanding of the genetics of these diseases. Too little is known about how to treat these patients.

Back to Top


What is an MPN?

What tests are important for an MPN patient as they go on their journey? MPN Expert, Dr. Srdan Verstovsek, explains.

Back to Top


Defining the MPN Blast Phase

Back to Top


Understanding Disease Burden Among MPNs

Back to Top


MPD-RC 112 Clinical Trial for High Risk Polycythemia Vera and Essential Thrombocythemia

"Ruben Mesa, M.D., hematologist at Mayo Clinic in Arizona, discusses MPD-RC 112, a randomized trial of pegylated interferon alfa-2a versus hydroxyurea therapy in the treatment of high risk polycythemia vera (PV) and high risk essential thrombocythemia (ET)."

Back to Top


Dr. John Camoriano, Mayo Clinic Scottsdale AZ

"Living well with blood disorders".

Back to Top


Top 10 Tips for Battling the Fatigue Associated with Myeloproliferative Neoplasms - Mayo Clinic

Ruben Mesa, M.D., hematologist and Deputy Director of the Mayo Clinic Cancer Center in Arizona, provides his top ten recommendations for battling the fatigue associated with a diagnosis of myeloproliferative neoplasm.

Back to Top


Myelofibrosis and Bone Marrow Transplant - Mayo Clinic

Ruben Mesa, M.D. and Veena Fauble, M.D., Mayo Clinic hematologists, discuss bone marrow transplant as a treatment option for patients diagnosed with myelofibrosis.

Back to Top


Ruben Mesa, M.D., hematologist at Mayo Clinic in Arizona, discusses the updates in the treatment and management of myelofibrosis.

Back to Top


Answering Common Patient Questions on Myeloproliferative Neoplasms - Mayo Clinic

Ruben Mesa, M.D., Chair of Hematology and Oncology at Mayo Clinic in Arizona, discusses common patient questions regarding myeloproliferative neoplasms with John Camoriano, M.D., medical oncology consultant at Mayo Clinic.

Back to Top